PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 6.5% After Earnings Miss

PTC Therapeutics, Inc. (NASDAQ:PTCT)’s stock price dropped 6.5% during mid-day trading on Friday after the company announced weaker than expected quarterly earnings. The stock traded as low as $66.48 and last traded at $65.3310. Approximately 212,432 shares traded hands during trading, a decline of 83% from the average daily volume of 1,217,086 shares. The stock had previously closed at $69.90.

The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same quarter last year, the business earned ($0.85) earnings per share. The company’s revenue was down 22.7% on a year-over-year basis.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Royal Bank Of Canada decreased their price objective on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Friday. Bank of America reduced their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a report on Friday. Barclays raised PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $68.00 to $119.00 in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group lifted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $80.73.

Insider Activity at PTC Therapeutics

In other news, CEO Matthew B. Klein sold 7,371 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the completion of the transaction, the chief executive officer owned 387,082 shares of the company’s stock, valued at $26,848,007.52. This represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric Pauwels sold 3,019 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $209,397.84. Following the sale, the insider directly owned 77,122 shares in the company, valued at $5,349,181.92. The trade was a 3.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 298,246 shares of company stock valued at $23,393,870. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently modified their holdings of the company. AlphaQuest LLC grew its stake in PTC Therapeutics by 337.7% during the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares during the period. Vise Technologies Inc. bought a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $486,000. Prudential Financial Inc. grew its position in shares of PTC Therapeutics by 35.5% during the 2nd quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock worth $4,115,000 after buying an additional 22,060 shares during the period. WCM Investment Management LLC bought a new stake in shares of PTC Therapeutics in the 3rd quarter valued at $8,919,000. Finally, Sector Gamma AS increased its stake in shares of PTC Therapeutics by 28.0% in the 3rd quarter. Sector Gamma AS now owns 118,112 shares of the biopharmaceutical company’s stock valued at $7,249,000 after acquiring an additional 25,862 shares in the last quarter.

PTC Therapeutics Trading Up 1.1%

The company has a market cap of $5.67 billion, a price-to-earnings ratio of 9.13 and a beta of 0.48. The stock’s 50-day moving average is $74.91 and its 200-day moving average is $67.91.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.